Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jun 2021

Grželj Jasna, Mlinarič-Raščan Irena, Marko Pij B, Marovt Maruška, Gmeiner Tanja, Šmid Alenka

Abstract excerpt

Methotrexate is used as first-line treatment of moderate to severe psoriasis. Despite the marked variability in treatment outcomes, no pharmacogenetic markers are currently used for personalised management of therapy. In this retrospective study, we investigated the effects of genetic predisposition on efficacy and toxicity of low-dose methotrexate in a cohort of 137 patients with moderate to severe plaque...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatologic Agents
Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3B

Share to Methotrexate

Share to Multidrug Resistance-Associated Protein 2

Share to Pharmacogenomic Testing

Share to Psoriasis

Share to Registries

Source

Identifiers

PMID: 33714108
DOI: 10.1016/j.biopha.2021.111456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis.PMID 33714108Read ↗

Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.Semantic proximity Read ↗

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.Semantic proximity Read ↗

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?Semantic proximity Read ↗

Advances in individual prediction of methotrexate toxicity: a reviewSemantic proximity Read ↗

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated ReviewSemantic proximity Read ↗

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is PromisingSemantic proximity Read ↗

Influence of FPGS rs1544105 and GGH rs3758149 Gene Polymorphisms on Methotrexate Pharmacogenetics.Semantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Semantic proximity Read ↗

Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.Semantic proximity Read ↗

MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in PsoriasisSemantic proximity Read ↗

Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.